Denosumab Global Safety Assessment Among Women With Postmenopausal Osteoporosis and Men With Osteoporosis in Multiple Observational Databases
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Denosumab (Primary) ; Osteoporosis therapies
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions
- Sponsors Amgen
- 05 Dec 2017 Planned End Date changed from 23 May 2023 to 25 May 2020.
- 05 Dec 2017 Planned primary completion date changed from 23 May 2023 to 25 May 2020.
- 11 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.